Table 1. Characteristics of trials included in the Meta-analysis.
| Study ID | country | Trial phase | N(T/C) | Male (T/C,%) |
Ages (T/C,Years) |
Interventions | outcomes | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TKI-group | Non-TKI-group | ORR | OS | CNS-TTP | PFS | Adverse event (grade≥3) | |||||||
| Lee et al. 2014 | Britain | II | 40/40 | 37.5/52.5 | 61.3/62.2 | erlotinib+WBRT | placebo+WBRT | N | Y | Y | N | Y | |
| Zhuang et al. 2013 | China | II | 23/31 | 43/42 | 60/63 | erlotinib+WBRT | WBRT | Y | Y | Y | Y | Y | |
| Sperduto et al. 2013 | America | III | 41/44 | N | 61/64 | erlotinib+WBRT/SRS | WBRT/SRS | N | Y | Y | N | Y | |
| Fu et al. 2012 | China | N | 38/123 | N | N | gefitinib+WBRT/SRS | WBRT/SRS | Y | N | N | N | Y | |
| Pesce et al. 2011 | Switzerland | II | 16/43 | 56/63 | 57/63 | gefitinib+WBRT | TMZ+WBRT | N | Y | N | N | Y | |
| Wang et al. 2014 | China | N | 37/36 | 67.6/63.9 | 61/62 | gefitinib+3D-CRT | VMP+3D-CRT | Y | Y | N | N | Y | |
| Cai et al. 2014 | China | N | 104/178 | 59.6/66.3 | 65/65 | TKI+WBRT/SRS/S | WBRT/SRS/S | N | Y | Y | N | N | |
| Fan et al. 2013 | China | N | 75/111 | 57.3/73.0 | 57/57 | TKI+WBRT/SRS/S | chemotherapy+WBRT/SRS/S | N | Y | N | N | N | |
Abbreviation: N(T/C): number of patients(test group/control group); ORR: object response rate; OS: overall survival; CNS-TTP: time to central nerves system/neurological progression / neurological progression-free survival/progression-free survival of intracranial disease/local progression-free survival; PFS: progression-free survival; N: no mention in the paper; Y: have mentioned in the paper.